Treprostinil: Medgend

Treprostinil FDA Approved Drugs

ORENITRAM [Treprostinil Diolamine^{C₂₃H₃₄O₅C₄H₁₁NO₂}]

eq 0.125mg base (oral tablet, extended release)

eq 0.25mg base (oral tablet, extended release)

eq 1mg base (oral tablet, extended release)

eq 2.5mg base (oral tablet, extended release)

eq 5mg base (oral tablet, extended release)

United Therap^{Dec 20, 2013}

Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil.
Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1)..

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

REMODULIN [Treprostinil^{C₂₃H₃₄O₅}]

10mg/ml (iv (infusion), subcutaneous injectable)

1mg/ml (iv (infusion), subcutaneous injectable)

2.5mg/ml (iv (infusion), subcutaneous injectable)

United Therap^{May 21, 2002}

Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration.
Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

TYVASO [Treprostinil^{C₂₃H₃₄O₅}]

0.6mg/ml (inhalation solution)

United Therap^{Jul 30, 2009}

Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device.
Treatment of pulmonary hypertension by inhalation.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.